Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 10/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ap18 5 SCHEMBL1499479 | 1.00 | TRPA1 (1.00) | TRPA1CYP2C9SIGMAR1ABCB11HDAC3 | |
| Ap18 5 SCHEMBL1962033 | 1.00 | TRPA1 (1.00) | TRPA1CYP2C9SIGMAR1ABCB11HDAC3 | |
| Ap18 5 SCHEMBL12552586 | 1.00 | TRPA1 (1.00) | TRPA1CYP2C9SIGMAR1ABCB11HDAC3 | |
| Ap18 5 SCHEMBL1499542 | 1.00 | TRPA1 (1.00) | TRPA1CYP2C9SIGMAR1ABCB11HDAC3 | |
| SCHEMBL11767293 | 0.81 | TRPA1 (0.68) | TRPA1CYP2C9SIGMAR1ABCB11HDAC3 | |
| SCHEMBL28252409 | 0.79 | TRPA1 (0.66) | TRPA1CYP2C9SIGMAR1ABCB11FBP1 | |
| SCHEMBL3668616 | 0.76 | TRPA1 (0.61) | TRPA1SIGMAR1ABCB11 | |
| SCHEMBL3668618 | 0.76 | TRPA1 (0.61) | TRPA1SIGMAR1ABCB11 | |
| SCHEMBL22995639 | 0.75 | TRPA1 (0.60) | TRPA1CYP2C9HDAC3HDAC4HDAC1 | |
| SCHEMBL22995643 | 0.75 | TRPA1 (0.60) | TRPA1CYP2C9HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119483579-A | Signal transmission system and method in isolation driving circuit | 苏州炬仁半导体有限公司 | 2025-02-18 | — | — | CN | claimed |
| CN-222283315-U | Signal conversion circuit capable of outputting multi-channel video signals for splicing display | 深圳市华创科智技术科技有限公司 | 2024-12-31 | — | — | CN | claimed |
| EP-4434802-A1 | FUEL CELL SYSTEMS WITH ENDURANCE BRAKING SUPPORT | VOLVO TRUCK CORPORATION (SE) | 2024-09-25 | — | — | EP | claimed |
| CN-118684620-A | Betel nut alkaloid and preparation method and application thereof | 暨南大学 | 2024-09-24 | — | — | CN | claimed |
| US-20240251664-A1 | LIGHT EMITTING ELEMENT AND AMINE COMPOUND FOR THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-07-25 | — | — | US | claimed |
| CN-117119132-A | GPU video input interface VIP | 中国船舶集团有限公司第七一六研究所 | 2023-11-24 | — | — | CN | claimed |
| US-20230372350-A1 | ASTROCYTIC TRPA1 CHANNEL INHIBITION AS A NOVEL NEUROPROTECTIVE THERAPEUTIC TARGET IN THE PRODROMAL PHASES OF ALZHEIMER'S DISEASE | UNIVERSITE GRENOBLE ALPES (FR) | 2023-11-23 | — | — | US | claimed |
| EP-4213823-A1 | ASTROCYTIC TRPA1 CHANNEL INHIBITION AS A NOVEL NEUROPROTECTIVE THERAPEUTIC TARGET IN THE PRODROMAL PHASES OF ALZHEIMER'S DISEASE | Université Grenoble Alpes (FR) | 2023-07-26 | — | — | EP | claimed |
| CN-116437920-A | Astrocyte TRPA1 channel inhibition as a novel neuroprotective therapeutic target for the precursor phase of Alzheimer's disease | 格勒诺布尔大学 | 2023-07-14 | — | — | CN | claimed |
| CN-115967620-A | Method and device for automatically realizing directional matching of ground station network equipment | 中国卫通集团股份有限公司 | 2023-04-14 | — | — | CN | claimed |
| WO-2022058946-A1 | ASTROCYTIC TRPA1 CHANNEL INHIBITION AS A NOVEL NEUROPROTECTIVE THERAPEUTIC TARGET IN THE PRODROMAL PHASES OF ALZHEIMER'S DISEASE | UNIVERSITÉ GRENOBLE ALPES (FR) | 2022-03-24 | — | — | WO | claimed |
| EP-4748447-A2 | INFLUENZA VIRUS VACCINES AND USES THEREOF | Icahn School of Medicine at Mount Sinai (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260143965-A1 | LIGHT EMITTING ELEMENT, AMINE COMPOUND FOR THE LIGHT EMITTING ELEMENT, AND DISPLAY DEVICE INCLUDING THE LIGHT EMITTING ELEMENT | SAMSUNG DISPLAY CO LTD (KR) | 2026-05-21 | — | — | US | disclosed |
| WO-2026107083-A2 | SHELF-STABLE LOXSH CATALYST SOLUTION COMPOSITIONS COMPRISING SOLUBLE HIGH HYDRIDE CONCENTRATIONS AND THE PROCESSES FOR PREPARING THEM | ALBEMARLE CORPORATION (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260062460-A1 | METHODS FOR TREATING ACUTE CORONARY SYNDROME USING APOA-1 FUSION PROTEINS | THERIPION, INC. (US) | 2026-03-05 | — | — | US | disclosed |
| EP-3954672-A1 | VERMICOMPOST PRODUCTION METHOD | Excelsior Inc. (JP) | 2022-02-16 | — | — | EP | disclosed |
| US-11241442-B2 | Methods of use for TRP channel antagonist-based combination cancer therapies | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-02-08 | — | — | US | disclosed |
| US-20220026803-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2022-01-27 | — | — | US | disclosed |
| US-20220026805-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2022-01-27 | — | — | US | disclosed |
| US-20220026804-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062460-A1 | METHODS FOR TREATING ACUTE CORONARY SYNDROME USING APOA-1 FUSION PROTEINS | PON1, APOB, APOL1 | TRPA1 4707/4885CYP2C9 1610/4885SIGMAR1 3120/4885 |
| US-20230372350-A1 | ASTROCYTIC TRPA1 CHANNEL INHIBITION AS A NOVEL NEUROPROTECTIVE THERAPEUTIC TARGET IN THE PRODROMAL PHASES OF ALZHEIMER'S DISEASE | TRPA1, APP, TRPV2 | TRPA1 1/4885CYP2C9 3399/4885SIGMAR1 1141/4885 |
| US-20260143965-A1 | LIGHT EMITTING ELEMENT, AMINE COMPOUND FOR THE LIGHT EMITTING ELEMENT, AND DISPLAY DEVICE INCLUDING THE LIGHT EMITTING ELEMENT | NR2E3, NR2E1, NR0B2 | TRPA1 377/4885CYP2C9 1201/4885SIGMAR1 475/4885 |
| US-20240251664-A1 | LIGHT EMITTING ELEMENT AND AMINE COMPOUND FOR THE SAME | NES, NFE2L2, NUCB2 | TRPA1 481/4885CYP2C9 863/4885SIGMAR1 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.